Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Neoplasia ; 11(4): 355-64, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19308290

ABSTRACT

The receptor tyrosine kinase MET is a major component controlling the invasive growth program in embryonic development and in invasive malignancies. The discovery of therapeutic antibodies against MET has been difficult, and antibodies that compete with hepatocyte growth factor (HGF) act as agonists. By applying phage technology and cell-based panning strategies, we discovered two fully human antibodies against MET (R13 and R28), which synergistically inhibit HGF binding to MET and elicit antibody-dependent cellular cytotoxicity. Cell-based phosphorylation assays demonstrate that R13 and R28 abrogate HGF-induced activation of MET, AKT1, ERK1/2, and HGF-induced migration and proliferation. FACS experiments suggest that the inhibitory effect is mediated by "locking" MET receptor in a state with R13, which then increases avidity of R28 for the extracellular domain of MET, thus blocking HGF binding without activating the receptor. In vivo studies demonstrate that the combination of R13/28 significantly inhibited tumor growth in various colon tumor xenograft models. Inhibition of tumor growth was associated with induction of hypoxia. Global gene expression analysis shows that inhibition of HGF/MET pathway significantly upregulated the tumor suppressors KLF6, CEACAM1, and BMP2, the negative regulator of phosphatidylinositol-3-OH-kinase PIK3IP1, and significantly suppressed SCF and SERPINE2, both enhancers of proliferation and invasiveness. Moreover, in an experimental metastasis model, R13/28 increased survival by preventing the recurrence of otherwise lethal lung metastases. Taken together, these results underscore the utility of a dual-antibody approach for targeting MET and possibly other receptor tyrosine kinases. Our approach could be expanded to drug discovery efforts against other cell surface proteins.


Subject(s)
Antibodies, Monoclonal/immunology , Antibody Specificity/immunology , Antineoplastic Agents/immunology , Colonic Neoplasms/immunology , Proto-Oncogene Proteins/immunology , Receptors, Growth Factor/immunology , Animals , Antibodies, Monoclonal/pharmacology , Antineoplastic Agents/pharmacology , Blotting, Western , Cell Movement , Cell Proliferation , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Gene Expression Profiling , Hepatocyte Growth Factor/antagonists & inhibitors , Humans , Male , Mice , Mice, SCID , Proto-Oncogene Proteins c-met , Signal Transduction/drug effects , Xenograft Model Antitumor Assays
2.
Clin Cancer Res ; 14(16): 5188-97, 2008 Aug 15.
Article in English | MEDLINE | ID: mdl-18698037

ABSTRACT

PURPOSE: The epidermal growth factor receptor family member HER3 is overexpressed in diverse human cancers and has been associated with poor prognosis in breast, lung, and ovarian cancer. However, the relevance of HER3 with regard to its prognostic significance and function in primary melanoma and metastases remains largely elusive. EXPERIMENTAL DESIGN: HER3 protein expression was analyzed immunohistochemically using tissue microarrays of 130 primary melanoma and 87 metastases relative to established clinical variables. The possibility of an influence of HER3 on melanoma cell proliferation, migration, invasion, and chemotherapy-induced apoptosis was studied in human melanoma cell lines. RESULTS: We show that HER3 is frequently expressed in malignant melanoma and metastases at elevated levels. High HER3 expression may serve as a prognostic marker because it correlates with cell proliferation, tumor progression, and reduced patient survival. Suppression of HER3 expression by RNA interference reduces melanoma cell proliferation, migration, and invasion in vitro. In addition, down-regulation of HER3 synergistically enhances dacarbazine-induced apoptosis. Moreover, monoclonal antibodies specific for the extracellular portion of HER3 efficiently block heregulin-induced proliferation, migration, and invasion of melanoma cell lines. CONCLUSION: Our results provide novel insights into the role of HER3 in melanoma and point out new possibilities for therapeutic intervention.


Subject(s)
Biomarkers, Tumor/analysis , Melanoma/metabolism , Melanoma/pathology , Receptor, ErbB-3/biosynthesis , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Apoptosis/physiology , Blotting, Western , Cell Line, Tumor , Cell Movement/physiology , Cell Proliferation , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Melanoma/mortality , Middle Aged , Prognosis , RNA Interference , Reverse Transcriptase Polymerase Chain Reaction , Skin Neoplasms/mortality , Tissue Array Analysis
3.
Neoplasia ; 10(4): 340-7, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18392135

ABSTRACT

Midkine (MDK) is a heparin-binding growth factor involved in growth, survival, migration, and differentiation of various target cells and dysregulation of MDK signaling is implicated in a variety of inflammatory diseases and cancers. Although MDK has been reported to act on endothelial cells and to have proangiogenic effects, the exact role of MDK in angiogenesis is poorly defined. Here, we report that MDK is actually a modulator of angiogenesis and that it can abrogate the vascular endothelial growth factor A (VEGF-A)-induced proliferation of human microvascular endothelial cells in vitro through the downregulation of proangiogenic cytokines and through the upregulation of the antiangiogenic factor, tissue inhibitor of metalloproteinase 2. Phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR-2) and of downstream signaling molecules, such as phosphatidylinositol-3-kinase and mitogen-activated protein kinases, is also impaired. Moreover, MDK downregulates VEGF-A-induced neovascularization and vascular permeability in vivo. We propose a model in which MDK is a new modulator of the VEGF-A-VEGFR-2 axis.


Subject(s)
Endothelium, Vascular/metabolism , Nerve Growth Factors/physiology , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Animals , Blotting, Western , Capillary Permeability , Chickens , Chorioallantoic Membrane/pathology , Corneal Neovascularization/metabolism , Endothelium, Vascular/cytology , Enzyme-Linked Immunosorbent Assay , Female , Humans , In Vitro Techniques , Mice , Mice, Inbred BALB C , Midkine , Mitogen-Activated Protein Kinases/metabolism , Neoplasm Proteins/physiology , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Rats , Signal Transduction , Skin , Tissue Inhibitor of Metalloproteinase-2/metabolism , Transforming Growth Factor alpha/metabolism , Tumor Necrosis Factor-alpha/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism
4.
Proc Natl Acad Sci U S A ; 102(44): 15901-6, 2005 Nov 01.
Article in English | MEDLINE | ID: mdl-16247015

ABSTRACT

Metastasis of primary tumors leads to a very poor prognosis for patients suffering from cancer. Although it is well established that not every tumor will eventually metastasize, it is less clear whether primary tumors acquire genetic alterations in a stochastic process at a late stage, which make them invasive, or whether genetic alterations acquired early in the process of tumor development drive primary tumor growth and determine whether this tumor is going to be metastatic. To address this issue, we tested genes identified in a large-scale comparative genomic hybridization analysis of primary tumor for their ability to confer metastatic properties on a cancer cell. We identified amplification of the ACK1 gene in primary tumors, which correlates with poor prognosis. We further show that overexpression of Ack1 in cancer cell lines can increase the invasive phenotype of these cells both in vitro and in vivo and leads to increased mortality in a mouse model of metastasis. Biochemical studies show that Ack1 is involved in extracellular matrix-induced integrin signaling, ultimately activating signaling processes like the activation of the small GTPase Rac. Taken together, this study supports a theory from Bernards and Weinberg [Bernards, R. & Weinberg, R. A. (2002) Nature 418, 823], which postulates that the tendency to metastasize is largely predetermined.


Subject(s)
Gene Amplification , Neoplasm Metastasis/genetics , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/physiology , Animals , Cell Line, Tumor , Crk-Associated Substrate Protein/metabolism , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Integrin alpha3beta1/metabolism , Lung Neoplasms/secondary , Mice , Neoplasm Transplantation , Prognosis , Protein-Tyrosine Kinases/metabolism , Signal Transduction , Transplantation, Heterologous , Tumor Cells, Cultured , rac GTP-Binding Proteins/metabolism
5.
Int J Cancer ; 115(4): 519-27, 2005 Jul 01.
Article in English | MEDLINE | ID: mdl-15704104

ABSTRACT

Two members of the EGF receptor family, HER2 and HER3, act as key oncogenes in breast cancer cells. A MAb against HER2, trastuzumab, interferes with HER2 signaling and istherapeutically effective in humans. Here, we explored the biologic effects of an antibody against HER3 (alpha-HER3ECD) in the invasive breast cancer cell lines MCF-7ADR and MDA-MB-468. Pretreating the breast cancer cells with alpha-HER3ECD prior to Heregulin stimulation caused significant reduction of the migratory and proliferative properties. This reduction is due to a substantial decrease in the tyrosine phosphorylation content of HER2 and to a modification of the HER2/HER3 association, which ultimately inhibits the activity of the downstream effectors phosphatidyinositol-3-OH-kinase and c-jun-terminal kinase. Furthermore, HER3 is internalized and not activated by HRG after pretreatment with alpha-HER3ECD. Our data reinforce the notion that HER3 could be a key target in cancer drug design and show the great potential of anti-HER3 antibodies for the therapy of breast cancer and other malignancies characterized by overexpression of HER3.


Subject(s)
Antibodies, Monoclonal/pharmacology , Breast Neoplasms/immunology , Receptor, ErbB-3/immunology , 3T3 Cells , Animals , Biotinylation , Cell Division/drug effects , Cell Line, Tumor , Chemotaxis/drug effects , Female , Humans , Mice , Neuregulin-1/pharmacology , Signal Transduction/drug effects , Signal Transduction/immunology
6.
Int J Cancer ; 113(5): 689-98, 2005 Feb 20.
Article in English | MEDLINE | ID: mdl-15499613

ABSTRACT

Receptor tyrosine kinases of the EGFR family transmit extracellular signals that control diverse cellular functions such as proliferation, differentiation and survival. Signaling function of a member of this family, HER3, is believed to be impaired due to deviations in its kinase consensus motifs. Here we address the functional role and signaling mechanisms of HER3. HER3 preferentially forms heterodimers with HER2 inducing the most potent mitogenic signal among EGFR family members. Our data show that in a glioma-derived cell line the cytoplasmic tyrosine kinase PYK2 is constitutively associated with HER3 and that stimulation with Heregulin results in PYK2 tyrosine phosphorylation. HER3, but not HER2, mediates the phosphorylation of the C-terminal region of PYK2 to promote a mitogenic response through activation of the MAPK pathway. A central role of PYK2 in signaling downstream of HER3 is substantiated by the demonstration that expression of a dominant-negative PYK2-KM construct abrogates the Heregulin-induced MAPK activity and inhibits the invasive potential of glioma cells. These results suggest a novel Heregulin/HER3-stimulated signaling pathway in glioblastoma-derived cell lines that involves phosphorylation of PYK2 and mediates invasiveness of glioma cells.


Subject(s)
Glioma/metabolism , Neoplasm Invasiveness/pathology , Neuregulin-1/pharmacology , Protein-Tyrosine Kinases/metabolism , Receptor, ErbB-3/metabolism , Tyrosine/metabolism , Focal Adhesion Kinase 2 , Genes, Dominant , Glioma/pathology , Humans , Mitogen-Activated Protein Kinases/metabolism , Neuregulins , Phosphorylation/drug effects , Signal Transduction , Tumor Cells, Cultured
7.
Biotechniques ; 37(6): 940-2, 944, 946, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15597543

ABSTRACT

The chick embryonic metastasis (CEM) assay is a fast in vivo method to investigate the invasive properties of tumor cells. Until now, most quantification methods were semiquantitative and time-consuming. Here we describe a rapid quantification method using TaqMan technology to quantify the invaded tumor cells in the chorioallantoic membrane of fertilized eggs. This method is based on specific detection of human ALU sequences. Moreover, it provides high sensitivity over a wide linearity range.


Subject(s)
Colonic Neoplasms/pathology , Colonic Neoplasms/secondary , DNA, Neoplasm/analysis , Melanoma/pathology , Melanoma/secondary , Neoplasm Invasiveness/pathology , Polymerase Chain Reaction/methods , Alu Elements/genetics , Animals , Cell Line, Tumor , Chick Embryo , Colonic Neoplasms/genetics , DNA, Neoplasm/genetics , Humans , Melanoma/genetics , Mice , Neoplasm Invasiveness/genetics , Reproducibility of Results , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...